Table 3.

Efficacy of treatment with the cetuximab + oxaliplatin backbone regimen in patients with MSI-high advanced/metastatic CRC

	MSI high (n =4)
Tumor response
CR	1
PR	0
SD	3
PD	0
NE	0
RR (%)	25.0 (0.0-80.6)
DCR (%)	100.0 (39.8-100.0)
Median DpR (%)	-25.1 (-100, 7.9)
Median PFS (months)	13.7 (9.0-13.7)
Median OS (months)	21.8 (16.7-26.8)

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluated; RR, response rate; DCR, disease control rate; DpR, depth of response; PFS, progression-free survival; OS, overall survival; MSI, microsatellite instability